Literature DB >> 27886408

Role of ROCK2 in CD4+ cells in allergic airways responses in mice.

D I Kasahara1, J A Mathews1, F M C Ninin1, A P Wurmbrand1, J K Liao2, S A Shore1.   

Abstract

BACKGROUND: Rho kinases (ROCKs) contribute to allergic airways disease. ROCKs also play a role in lymphocyte proliferation and migration.
OBJECTIVE: To determine the role of ROCK2 acting within CD4+ cells in allergic airways responses.
METHODS: ROCK2-haploinsufficient (ROCK2+/- ) and wild-type mice were sensitized with ovalbumin (OVA). ROCK2+/- mice then received either CD4+ cells from ROCK2-sufficient OVA TCR transgenic (OT-II) mice or saline i.v. 48 h before challenge with aerosolized OVA. Wild-type mice received saline before challenge. Allergic airways responses were measured 48 h after the last challenge. Allergic airways responses were also assessed in mice lacking ROCK2 only in CD4+ cells (ROCK2CD4Cre mice) vs. control (CD4-Cre and ROCK2flox/flox ) mice.
RESULTS: OVA-induced increases in bronchoalveolar lavage lymphocytes, eosinophils, IL-13, IL-5, and eotaxin were reduced in ROCK2+/- vs. wild-type mice, as were airway hyperresponsiveness and mucous hypersecretion. In ROCK2+/- mice, adoptive transfer with CD4+ cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous hypersecretion to wild-type levels, whereas eotaxin and airway hyperresponsiveness were not affected. ROCK2 inhibitors reduced IL-13-induced release of eotaxin from airway smooth muscle (ASM), similar to effects of these inhibitors on ASM contractility. Despite the ability of adoptive transfer to restore allergic airways inflammation in ROCK2-insufficient mice, allergic inflammation was not different in ROCK2CD4Cre vs. control mice.
CONCLUSION: ROCK2 contributes to allergic airways responses likely via effects within ASM cells and within non-lymphocyte cells involved in lymphocyte activation and migration into the airways.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; animal models; asthma; basic mechanisms; lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 27886408      PMCID: PMC5280456          DOI: 10.1111/cea.12866

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  65 in total

1.  Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells.

Authors:  O Ghaffar; Q Hamid; P M Renzi; Z Allakhverdi; S Molet; J C Hogg; S A Shore; A D Luster; B Lamkhioued
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

Review 2.  Bronchial epithelium as a target for innovative treatments in asthma.

Authors:  Delphine Gras; Pascal Chanez; Isabelle Vachier; Aurélie Petit; Arnaud Bourdin
Journal:  Pharmacol Ther       Date:  2013-07-21       Impact factor: 12.310

3.  ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.

Authors:  O Nakagawa; K Fujisawa; T Ishizaki; Y Saito; K Nakao; S Narumiya
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

4.  The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils.

Authors:  T Adachi; R Vita; S Sannohe; S Stafford; R Alam; H Kayaba; J Chihara
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis.

Authors:  Ying-Min Zhang; Jacqueline Bo; George E Taffet; Jiang Chang; Jianjian Shi; Anilkumar K Reddy; Lloyd H Michael; Michael D Schneider; Mark L Entman; Robert J Schwartz; Lei Wei
Journal:  FASEB J       Date:  2006-05       Impact factor: 5.191

6.  LFA-1-induced T cell migration on ICAM-1 involves regulation of MLCK-mediated attachment and ROCK-dependent detachment.

Authors:  Andrew Smith; Madelon Bracke; Birgit Leitinger; Joanna C Porter; Nancy Hogg
Journal:  J Cell Sci       Date:  2003-06-10       Impact factor: 5.285

7.  Type I interleukin-1 receptor is required for pulmonary responses to subacute ozone exposure in mice.

Authors:  Richard A Johnston; Joseph P Mizgerd; Lesley Flynt; Lee J Quinton; Erin S Williams; Stephanie A Shore
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

8.  Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death.

Authors:  Dean Thumkeo; Jeongsin Keel; Toshimasa Ishizaki; Masaya Hirose; Kimiko Nonomura; Hiroko Oshima; Masanobu Oshima; Makoto M Taketo; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes.

Authors:  Giuseppe Bardi; Verena Niggli; Pius Loetscher
Journal:  FEBS Lett       Date:  2003-05-08       Impact factor: 4.124

10.  ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury.

Authors:  Kensuke Noma; Yoshiyuki Rikitake; Naotsugu Oyama; Guijun Yan; Pilar Alcaide; Ping-Yen Liu; Hongwei Wang; Daniela Ahl; Naoki Sawada; Ryuji Okamoto; Yukio Hiroi; Koichi Shimizu; Francis W Luscinskas; Jianxin Sun; James K Liao
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more
  3 in total

1.  Instillation of hyaluronan reverses acid instillation injury to the mammalian blood gas barrier.

Authors:  Ting Zhou; Zhihong Yu; Ming-Yuan Jian; Israr Ahmad; Carol Trempus; Brant M Wagener; Jean-Francois Pittet; Saurabh Aggarwal; Stavros Garantziotis; Weifeng Song; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-25       Impact factor: 5.464

Review 2.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

Review 3.  Rho signaling research: history, current status and future directions.

Authors:  Shuh Narumiya; Dean Thumkeo
Journal:  FEBS Lett       Date:  2018-05-24       Impact factor: 4.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.